“I am deeply moved and honored to be inducted into the SCI Hall of Fame,” stated Dr. Cohen. “Spinal cord injury is a devastating medical condition, but the scientific advances of the last 15 years have brought us closer than ever to bringing new therapies to clinical trials. My colleagues at Acorda and I are committed to achieving the company’s mission, to develop therapies that will treat SCI.”

Fifteen individuals or organizations were honored at the third annual SCI Hall of Fame induction ceremony and gala, which took place at the John F. Kennedy Center for the Performing Arts on the evening of November 6.

Marcie Roth, Executive Director and CEO of the NSCIA, noted, “The NSCIA is proud to recognize the vision of Dr. Cohen and the pioneering role that he and Acorda Therapeutics have played in bringing the attention of the Biotechnology and pharmaceutical industries to the development of new treatments to improve the lives of people with spinal cord injury.”

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, Multiple Sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of Spasticity. Acorda’s lead clinical product, Fampridine-SR, is in a Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, Regeneration and repair of the spinal cord and brain.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.